Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/1258
Title: Mitochondrial genome variation and prostate cancer: a review of the mutational landscape and application to clinical management.
Epworth Authors: Corcoran, Niall
Hovens, Christopher
Other Authors: Kalsbeek, Anton
Chan, Eva
Hayes, Vanessa
Keywords: Prostate Cancer
Mitochondrial Genome
mtDNA Variation
Biomarkers
Cancer Pathogenesis
Mitochondrial DNA
Mutations
Genetic Disease
Molecular Taxonomy
Metabolism
Nuclear Genome
Cancer Risk
Somatic Mutations
Heteroplasmy
Recurrent Prostate Cancer
Carcinogenic
Metabolism
Apoptosis
Australian Prostate Cancer Research Centre Epworth HealthCare, Victoria, Australia
Issue Date: Aug-2017
Publisher: Impact Journals
Citation: Oncotarget. 2017 Aug 4;8(41):71342-71357
Abstract: Prostate cancer is a genetic disease. While next generation sequencing has allowed for the emergence of molecular taxonomy, classification is restricted to the nuclear genome. Mutations within the maternally inherited mitochondrial genome are known to impact cancer pathogenesis, as a result of disturbances in energy metabolism and apoptosis. With a higher mutation rate, limited repair and increased copy number compared to the nuclear genome, the clinical relevance of mitochondrial DNA (mtDNA) variation requires deeper exploration. Here we provide a systematic review of the landscape of prostate cancer associated mtDNA variation. While the jury is still out on the association between inherited mtDNA variation and prostate cancer risk, we collate a total of 749 uniquely reported prostate cancer associated somatic mutations. Support exists for number of somatic events, extent of heteroplasmy, and rate of recurrence of mtDNA mutations, increasing with disease aggression. While, the predicted pathogenic impact for recurrent prostate cancer associated mutations appears negligible, evidence exists for carcinogenic mutations impacting the cytochrome c oxidase complex and regulating metastasis through elevated reactive oxygen species production. Due to a lack of lethal cohort analyses, we provide additional unpublished data for metastatic disease. Discussing the advantages of mtDNA as a prostate cancer biomarker, we provide a review of current progress of including elevated mtDNA levels, of a large somatic deletion, acquired tRNAs mutations, heteroplasmy and total number of somatic events (mutational load). We confirm via meta-analysis a significant association between mtDNA mutational load and pathological staging at diagnosis or surgery (p < 0.0001).
URI: http://hdl.handle.net/11434/1258
DOI: 10.18632/oncotarget.19926
URL: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=19926&path[]=63596
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/29050365
ISSN: 1949-2553
Journal Title: Oncotarget
Type: Journal Article
Affiliated Organisations: Laboratory for Human Comparative and Prostate Cancer Genomics, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
Medical Faculty, University of New South Wales, Randwick, New South Wales, Australia.
Departments of Urology and Surgery, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia.
Central Clinical School, University of Sydney, Camperdown, New South Wales, Australia.
Type of Clinical Study or Trial: Reviews/Systematic Reviews
Appears in Collections:Cancer Services
Epworth Prostate Centre

Files in This Item:
File Description SizeFormat 
Kalsbeek et al 2017.pdf1.94 MBAdobe PDFView/Open


Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.